Identification

Name
Olmesartan
Accession Number
DB00275  (APRD00223)
Type
Small Molecule
Groups
Approved, Investigational
Description

Olmesartan is an antihypertensive agent, which belongs to the class of medications called angiotensin II receptor blockers. It is indicated for the treatment of high blood pressure and is marketed under the name Olmetec®. The FDA label includes a black-box warning of injury and death to the fetus, so women of child-bearing age need to be warned and take the necessary precautions. Olmesartan is also contraindicated in diabetes mellitus patients taking aliskiren.

Structure
Thumb
Synonyms
  • 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
  • 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
External IDs
DE-092 / RNH-6270
Product Ingredients
IngredientUNIICASInChI Key
Olmesartan medoxomil6M97XTV3HD144689-63-4UQGKUQLKSCSZGY-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-olmesartanTablet20 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-olmesartanTablet40 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Act OlmesartanTablet40 mgOralActavis Pharma Company2017-05-01Not applicableCanada
Act OlmesartanTablet20 mgOralActavis Pharma Company2017-05-01Not applicableCanada
Auro-olmesartanTablet20 mgOralAuro Pharma Inc2017-05-01Not applicableCanada
Auro-olmesartanTablet5 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-olmesartanTablet40 mgOralAuro Pharma Inc2017-05-01Not applicableCanada
BenicarTablet, film coated20 mg/1OralCardinal Health2002-04-25Not applicableUs
BenicarTablet, film coated20 mg/1Oralbryant ranch prepack2002-04-25Not applicableUs
BenicarTablet, film coated40 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-02-222017-09-22Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-olmesartanTablet10 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-olmesartanTablet20 mgOralApotex Corporation2017-05-31Not applicableCanada
Apo-olmesartanTablet40 mgOralApotex Corporation2017-05-30Not applicableCanada
Olmesartan MedoxomilTablet, coated5 mg/1OralAscend Laboratories, LLC2017-04-24Not applicableUs
Olmesartan MedoxomilTablet, film coated20 mg/1OralZydus Pharmaceuticals Usa, Inc.2017-04-24Not applicableUs
Olmesartan MedoxomilTablet, film coated5 mg/1OralMylan Pharmaceuticals2016-10-26Not applicableUs
Olmesartan MedoxomilTablet, film coated40 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-04-01Not applicableUs
Olmesartan MedoxomilTablet, film coated5 mg/1OralAurobindo Pharma2017-04-24Not applicableUs
Olmesartan MedoxomilTablet, film coated40 mg/1OralTeva2017-04-24Not applicableUs
Olmesartan MedoxomilTablet, film coated20 mg/1OralMylan Institutional2016-11-10Not applicableUs
International/Other Brands
Erastapex / Golme / Olmetec / WinBP
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Ach-olmesartan HctzOlmesartan medoxomil (40 mg) + Hydrochlorothiazide (25 mg)TabletOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-olmesartan HctzOlmesartan medoxomil (20 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-olmesartan HctzOlmesartan medoxomil (40 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAccord Healthcare LimitedNot applicableNot applicableCanada
Act Olmesartan HctOlmesartan medoxomil (40 mg) + Hydrochlorothiazide (25 mg)TabletOralActavis Pharma Company2017-05-01Not applicableCanada
Act Olmesartan HctOlmesartan medoxomil (20 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Pharma Company2017-05-01Not applicableCanada
Act Olmesartan HctOlmesartan medoxomil (40 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Pharma Company2017-05-01Not applicableCanada
Amlodipine and olmesartan MedoxomilOlmesartan medoxomil (20 mg/1) + Amlodipine besylate (10 mg/1)TabletOralAscend Laboratories, LLC2017-08-14Not applicableUs
Amlodipine and olmesartan medoxomilOlmesartan medoxomil (20 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralJubilant Cadista Pharmaceuticals Inc.2017-05-15Not applicableUs
Amlodipine and Olmesartan MedoxomilOlmesartan medoxomil (40 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralApotex Corporation2017-08-15Not applicableUs
Amlodipine and Olmesartan MedoxomilOlmesartan medoxomil (20 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralSun Pharmaceutical Industries Limited2016-10-26Not applicableUs
Categories
UNII
8W1IQP3U10
CAS number
144689-24-7
Weight
Average: 446.5016
Monoisotopic: 446.206638728
Chemical Formula
C24H26N6O3
InChI Key
VTRAEEWXHOVJFV-UHFFFAOYSA-N
InChI
InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)
IUPAC Name
4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylic acid
SMILES
CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O

Pharmacology

Indication

For the treatment of hypertension.

Structured Indications
Pharmacodynamics

Olmesartan is a specific angiotensin II type 1 (AT1) receptor antagonist, which blocks the blood pressure increasing effects of angiotensin II via the renin-angiotensin-aldosterone system (RAAS). During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: AT1 and AT2. AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.

Mechanism of action

Olmesartan is an ARB that selectively inhibits the binding of angiotensin II to AT1, which is found in many tissues such as vascular smooth muscle and the adrenal glands. This effectively inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in a decrease in vascular resistance and blood pressure. Olmesartan is selective for AT1 and has a 12,500 times greater affinity for AT1 than the AT2 receptor. Also unlike the well-known ARB losartan, olmesartan does not have an active metabolite or possess uricosuric effects.

TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Human
Absorption

Bioavailability is about 26%. Food does not affect the bioavailability of olmesartan.

Volume of distribution

The volume of distribution is 17 L and olmesartan poorly crosses the blood brain barrier.

Protein binding

Highly bound to plasma proteins (99%) and does not penetrate red blood cells.

Metabolism

Olmesartan is rapidly and completely bioactivated by ester hydrolysis to olmesartan during absorption from the gastrointestinal tract. There is virtually no further metabolism of olmesartan.

Route of elimination

Olmesartan is elminated unchanged in the urine (35% to 50%) and the remainder in the feces.

Half life

The half life is approximately 13 hours.

Clearance
  • Total plasma cl=1.3 L/h
  • Renal cl=0.6 L/h
Toxicity

The main symptoms of overdose include low blood pressure and fast heartbeat.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Olmesartan Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Olmesartan.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Acemetacin.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Olmesartan.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Olmesartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Alminoprofen.Experimental
AlprenololOlmesartan may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanOlmesartan may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineOlmesartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Olmesartan.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Olmesartan.Approved, Illicit
AmphetamineAmphetamine may increase the hypotensive activities of Olmesartan.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Olmesartan.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Olmesartan is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Olmesartan is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Olmesartan.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Olmesartan is combined with Apremilast.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Olmesartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Olmesartan.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Olmesartan.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Atenolol.Approved
AvanafilAvanafil may increase the antihypertensive activities of Olmesartan.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Olmesartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Olmesartan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Olmesartan.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Olmesartan.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Olmesartan is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Benzydamine.Approved
BepridilOlmesartan may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Olmesartan.Approved
BethanidineBethanidine may increase the hypotensive activities of Olmesartan.Approved
BevoniumThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Olmesartan.Experimental
BimatoprostOlmesartan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Olmesartan.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Olmesartan.Approved, Investigational
BQ-123Olmesartan may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Olmesartan.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Olmesartan.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Olmesartan.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Olmesartan.Approved, Investigational
BupranololOlmesartan may increase the hypotensive activities of Bupranolol.Approved
CadralazineCadralazine may increase the hypotensive activities of Olmesartan.Experimental
CafedrineOlmesartan may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Olmesartan.Approved
CandesartanOlmesartan may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Candesartan cilexetil.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Olmesartan.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Olmesartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Celecoxib.Approved, Investigational
CeliprololOlmesartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Olmesartan.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Chlorthalidone.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Olmesartan is combined with Choline magnesium trisalicylate.Approved
CicletanineOlmesartan may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Olmesartan.Approved, Investigational
CiprofloxacinOlmesartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Olmesartan.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Olmesartan.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clonidine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clonixin.Approved
CloranololOlmesartan may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Olmesartan.Approved
ColesevelamThe serum concentration of Olmesartan can be decreased when it is combined with Colesevelam.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Olmesartan.Approved, Investigational
CryptenamineOlmesartan may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Olmesartan is combined with Curcumin.Investigational
CyclopenthiazideOlmesartan may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineOlmesartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideOlmesartan may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Olmesartan is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Olmesartan.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Olmesartan.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Olmesartan.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Delapril.Experimental
DeserpidineOlmesartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Olmesartan.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Olmesartan.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Diclofenamide.Approved
diethylnorspermineOlmesartan may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Olmesartan is combined with Diflunisal.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Olmesartan.Investigational
DiltiazemThe risk or severity of adverse effects can be increased when Olmesartan is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dipyridamole.Approved
DorzolamideOlmesartan may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Doxazosin.Approved
DrospirenoneOlmesartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Olmesartan is combined with Droxicam.Approved
DuloxetineOlmesartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Olmesartan is combined with E-6201.Investigational
EfonidipineOlmesartan may increase the hypotensive activities of Efonidipine.Approved, Investigational
EltrombopagThe serum concentration of Olmesartan can be increased when it is combined with Eltrombopag.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Olmesartan is combined with Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Olmesartan.Experimental
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Olmesartan.Approved
EpanololOlmesartan may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Olmesartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Olmesartan.Approved
EpoprostenolOlmesartan may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Olmesartan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ethenzamide.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Olmesartan is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fenbufen.Approved
FenoldopamOlmesartan may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Feprazone.Experimental
Ferulic acidOlmesartan may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Olmesartan.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Flurbiprofen.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Olmesartan.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Furosemide.Approved, Vet Approved
GuacetisalThe risk or severity of adverse effects can be increased when Olmesartan is combined with Guacetisal.Experimental
GuanabenzOlmesartan may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Olmesartan.Approved
GuanazodineOlmesartan may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineOlmesartan may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Guanfacine.Approved, Investigational
GuanoclorOlmesartan may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzOlmesartan may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanOlmesartan may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Olmesartan.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Olmesartan.Experimental
HeparinHeparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
HexamethoniumOlmesartan may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Olmesartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Olmesartan.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideOlmesartan may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Olmesartan is combined with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Olmesartan.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Olmesartan is combined with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Olmesartan.Approved
IndapamideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Indapamide.Approved
IndenololOlmesartan may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Olmesartan.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Olmesartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Olmesartan.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Olmesartan.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Olmesartan.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Olmesartan.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Olmesartan.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Labetalol.Approved
LacidipineOlmesartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostOlmesartan may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Leflunomide.Approved, Investigational
LercanidipineOlmesartan may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Olmesartan.Approved, Investigational
LevodopaOlmesartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Olmesartan.Approved, Investigational
LinsidomineOlmesartan may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Olmesartan.Approved
LofexidineOlmesartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Losartan.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lumiracoxib.Approved, Investigational
MacitentanOlmesartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Olmesartan is combined with Magnesium salicylate.Approved
ManidipineOlmesartan may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Olmesartan.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Olmesartan is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Olmesartan is combined with Metamizole.Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Olmesartan.Approved
MethoserpidineOlmesartan may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Olmesartan.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Olmesartan is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Olmesartan.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Olmesartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Olmesartan.Approved
MetipranololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Olmesartan.Approved, Investigational
MetyrosineOlmesartan may increase the hypotensive activities of Metyrosine.Approved
MibefradilOlmesartan may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Olmesartan.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Minoxidil.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Olmesartan.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Olmesartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Olmesartan.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Olmesartan.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Olmesartan.Approved, Investigational
MuzolimineOlmesartan may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Olmesartan.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Olmesartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Naftifine.Approved
NaftopidilOlmesartan may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Naproxen.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Olmesartan.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Olmesartan.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Niflumic Acid.Approved
NiguldipineOlmesartan may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineOlmesartan may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nisoldipine.Approved
NitrendipineOlmesartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Olmesartan.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nitroprusside.Approved
ObinutuzumabOlmesartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Olmesartan.Withdrawn
OlopatadineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Olmesartan is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Oxaprozin.Approved
OxprenololOlmesartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Olmesartan.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Olmesartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Parthenolide.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Olmesartan.Approved, Vet Approved
PentoliniumOlmesartan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Olmesartan.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Olmesartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Olmesartan.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Olmesartan.Approved
PhenoxybenzamineOlmesartan may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Olmesartan.Withdrawn
PhentolamineOlmesartan may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Olmesartan.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Olmesartan.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Olmesartan.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Olmesartan is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Olmesartan.Withdrawn
Platelet Activating FactorOlmesartan may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideOlmesartan may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Olmesartan.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pranoprofen.Experimental, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Prazosin.Approved
PrimidonePrimidone may increase the hypotensive activities of Olmesartan.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Olmesartan.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Olmesartan.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Proquazone.Experimental
PTC299The risk or severity of adverse effects can be increased when Olmesartan is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Olmesartan.Approved
RamiprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Olmesartan.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Olmesartan.Approved
RemikirenRemikiren may increase the hypotensive activities of Olmesartan.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Olmesartan.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Olmesartan.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Olmesartan is combined with Riociguat.Approved
RisperidoneOlmesartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabOlmesartan may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Olmesartan.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Olmesartan.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Olmesartan.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Olmesartan.Approved
SafrazineSafrazine may increase the hypotensive activities of Olmesartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Olmesartan is combined with Salsalate.Approved
SaprisartanOlmesartan may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Olmesartan.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Olmesartan.Approved, Investigational, Vet Approved
SelexipagOlmesartan may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Olmesartan is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Olmesartan is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Olmesartan is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Olmesartan.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Olmesartan.Approved, Investigational
SitaxentanOlmesartan may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Olmesartan.Approved
Sodium phosphateOlmesartan may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sotalol.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Olmesartan is combined with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Olmesartan.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Olmesartan.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Olmesartan.Approved, Investigational
TalinololOlmesartan may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Olmesartan.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tarenflurbil.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Telmisartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Terazosin.Approved
TeriflunomideThe serum concentration of Olmesartan can be increased when it is combined with Teriflunomide.Approved
TerlipressinOlmesartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineOlmesartan may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Olmesartan.Approved, Investigational, Withdrawn
TheodrenalineOlmesartan may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Olmesartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Olmesartan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Olmesartan.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tiaprofenic acid.Approved
TiboloneOlmesartan may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenOlmesartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Olmesartan is combined with Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Olmesartan.Approved
TizanidineThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tizanidine.Approved
TolazolineOlmesartan may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Olmesartan.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tolmetin.Approved
TolonidineOlmesartan may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Olmesartan.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Olmesartan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Olmesartan.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Olmesartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Olmesartan.Approved
TravoprostOlmesartan may increase the hypotensive activities of Travoprost.Approved
TreprostinilOlmesartan may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Olmesartan.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Olmesartan is combined with Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tribenoside.Experimental
TrichlormethiazideOlmesartan may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Olmesartan.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Olmesartan.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Olmesartan.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Olmesartan is combined with Triptolide.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Olmesartan.Approved, Investigational
UnoprostoneOlmesartan may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Olmesartan.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Olmesartan is combined with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Olmesartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Olmesartan.Approved
VerapamilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Verapamil.Approved
VincamineOlmesartan may increase the hypotensive activities of Vincamine.Experimental
VinpocetineOlmesartan may increase the hypotensive activities of Vinpocetine.Investigational
XipamideOlmesartan may increase the hypotensive activities of Xipamide.Experimental
XylometazolineOlmesartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Olmesartan.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Olmesartan is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Olmesartan is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Olmesartan is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Olmesartan is combined with Zomepirac.Withdrawn
Food Interactions
  • Food does not affect the bioavailability of olmesartan.

References

Synthesis Reference

Lilach Hedvati, Gideon Pilarsky, "Preparation of olmesartan medoxomil." U.S. Patent US20060069141, issued March 30, 2006.

US20060069141
General References
Not Available
External Links
Human Metabolome Database
HMDB14420
KEGG Drug
D01204
PubChem Compound
158781
PubChem Substance
46508275
ChemSpider
139674
BindingDB
50241364
ChEBI
48416
ChEMBL
CHEMBL1516
Therapeutic Targets Database
DAP001412
PharmGKB
PA164742950
HET
OLM
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Olmesartan
ATC Codes
C09DA08 — Olmesartan medoxomil and diureticsC09CA08 — Olmesartan medoxomilC09DX03 — Olmesartan medoxomil, amlodipine and hydrochlorothiazideC09DB02 — Olmesartan medoxomil and amlodipine
AHFS Codes
  • 24:32.08 — Angiotensin Ii Receptor Antagonists
PDB Entries
4zud
FDA label
Download (179 KB)
MSDS
Download (58.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers7
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHypertensive1
1Not Yet RecruitingBasic ScienceHealthy Volunteers1
2CompletedTreatmentChronic Glomerulonephritis / Diabetic Nephropathies1
2CompletedTreatmentHypertensive4
2Not Yet RecruitingTreatmentCoronary Syndrome1
2, 3CompletedTreatmentHypertensive1
3CompletedPreventionCardiovascular Disease (CVD) / Kidney Diseases / Type 2 Diabetes Mellitus1
3CompletedTreatmentArrythmias / Heart Diseases / Nonvalvular Atrial Fibrillation1
3CompletedTreatmentAtherosclerosis1
3CompletedTreatmentAtherosclerotic Cardiovascular Diseases / Hypertension,Essential1
3CompletedTreatmentChronic Heart Failure (CHF)1
3CompletedTreatmentDiabetic Nephropathies / Proteinuria / Renal Diseases / Type 2 Diabetes Mellitus1
3CompletedTreatmentDiabetic Nephropathies / Proteinuria / Type 2 Diabetes Mellitus1
3CompletedTreatmentDyslipidemias / Hypertensive1
3CompletedTreatmentHypertension,Essential14
3CompletedTreatmentHypertension,Essential / Impaired Renal Function1
3CompletedTreatmentHypertensive7
3CompletedTreatmentHypertensive / Metabolic Syndromes2
3CompletedTreatmentSafety1
3Not Yet RecruitingTreatmentArterial Hypertension1
3Not Yet RecruitingTreatmentEssential Arterial Hypertension1
3RecruitingTreatmentHyperlipidemias / Hypertensive1
3RecruitingTreatmentSafety and Efficacy og Azilsartan in Chinese Hypertension Patients1
3Unknown StatusTreatmentHypertension,Essential1
4CompletedNot AvailableHypertensive1
4CompletedPreventionBMI >27 kg/m2 / Hypertensive / Obese / Prehypertension1
4CompletedPreventionCardiovascular Disease (CVD) / Hypertensive1
4CompletedTreatmentDrug Interaction of Olmesartan in Healthy Chinese Volunteers1
4CompletedTreatmentEssential,Hypertension1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHypertensive9
4CompletedTreatmentHypertensive / Insulin Resistance / Metabolic Syndromes1
4CompletedTreatmentHypertensive / Type 2 Diabetes Mellitus1
4RecruitingPreventionBlood Pressures / Hypertensive / Strokes1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4RecruitingTreatmentEfficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension1
4RecruitingTreatmentPeripheral Artery Disease With Intermittent Claudication1
4TerminatedTreatmentCarotid Plaques / Hypertension,Essential1
4Unknown StatusTreatmentCoronary Artery Atherosclerosis1
4Unknown StatusTreatmentHypertensive2
4WithdrawnTreatmentHypertensive1
Not AvailableCompletedNot AvailableExercise Training / Vascular Function1
Not AvailableCompletedNot AvailableHypertensive1
Not AvailableCompletedPreventionImpaired Glucose Tolerance (IGT) / Prediabetic State1
Not AvailableCompletedTreatmentHypertension,Essential1
Not AvailableCompletedTreatmentHypertensive1
Not AvailableCompletedTreatmentHypertensive / Obstructive Sleep Apnea (OSA)1
Not AvailableRecruitingNot AvailableHypertension,Essential1
Not AvailableUnknown StatusNot AvailableHypertensive1

Pharmacoeconomics

Manufacturers
  • Daiichi sankyo inc
  • Daiichi Sankyo
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOral10 mg
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
Tablet, coatedOral20 mg/1
Tablet, coatedOral40 mg/1
Tablet, coatedOral5 mg/1
TabletOral20 mg
TabletOral40 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Benicar 5 mg tablet12.81USD tablet
Benicar hct 40-25 mg tablet4.93USD tablet
Benicar hct 40-12.5 mg tablet4.67USD tablet
Benicar hct 20-12.5 mg tablet3.94USD tablet
Benicar 40 mg tablet3.74USD tablet
Benicar 20 mg tablet2.97USD tablet
Olmetec 20 mg Tablet1.04USD tablet
Olmetec 40 mg Tablet1.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2061607No1999-01-192012-02-20Canada
US5616599Yes1996-10-252016-10-25Us
US6878703Yes2002-05-192022-05-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)175-180 °CNot Available
logP5.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0105 mg/mLALOGPS
logP2.98ALOGPS
logP2.14ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)0.91ChemAxon
pKa (Strongest Basic)5.57ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area129.81 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity137.32 m3·mol-1ChemAxon
Polarizability47.46 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier-0.8719
Caco-2 permeable-0.6865
P-glycoprotein substrateSubstrate0.7247
P-glycoprotein inhibitor INon-inhibitor0.5917
P-glycoprotein inhibitor IIInhibitor0.6029
Renal organic cation transporterNon-inhibitor0.807
CYP450 2C9 substrateNon-substrate0.7429
CYP450 2D6 substrateNon-substrate0.8602
CYP450 3A4 substrateNon-substrate0.5149
CYP450 1A2 substrateNon-inhibitor0.782
CYP450 2C9 inhibitorInhibitor0.5816
CYP450 2D6 inhibitorNon-inhibitor0.8059
CYP450 2C19 inhibitorInhibitor0.6604
CYP450 3A4 inhibitorInhibitor0.7409
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8396
Ames testNon AMES toxic0.6203
CarcinogenicityNon-carcinogens0.6871
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6599 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9254
hERG inhibition (predictor II)Non-inhibitor0.6427
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a6r-0692700000-11f020dfbb889ac85e4e

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Phenyltetrazoles and derivatives / 1,2,4,5-tetrasubstituted imidazoles / Carbonylimidazoles / N-substituted imidazoles / Tertiary alcohols / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds
show 4 more
Substituents
Biphenyl / Phenyltetrazole / 1,2,4,5-tetrasubstituted imidazole / Imidazole-4-carbonyl group / N-substituted imidazole / Azole / Imidazole / Heteroaromatic compound / Tertiary alcohol / Tetrazole
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
biphenylyltetrazole (CHEBI:48416)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Koike H, Sada T, Mizuno M: In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens Suppl. 2001 Jun;19(1):S3-14. [PubMed:11451212]
  3. Ochiai K, Hu Q, Lee J, Mansoor A, Liu J, Wang X, Gong G, Murakami Y, Ishibashi Y, Shimada T, Zhang J: Functional and bioenergetic consequences of AT1 antagonist olmesartan medoxomil in hearts with postinfarction LV remodeling. J Cardiovasc Pharmacol. 2006 May;47(5):686-94. [PubMed:16775509]
  4. Warner GT, Jarvis B: Olmesartan medoxomil. Drugs. 2002;62(9):1345-53; discussion 1354-6. [PubMed:12076183]
  5. Mire DE, Silfani TN, Pugsley MK: A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol. 2005 Nov;46(5):585-93. [PubMed:16220064]
  6. Kreutz R, Bolbrinker J, Huber M: Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. Clin Drug Investig. 2006;26(1):29-34. [PubMed:17163232]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053]
  2. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T: OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9. Epub 2006 Feb 24. [PubMed:16501004]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T: OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9. Epub 2006 Feb 24. [PubMed:16501004]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T: OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9. Epub 2006 Feb 24. [PubMed:16501004]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34